'Breakthrough' mRNA cancer drug cuts melanoma recurrence in major trial
WASHINGTON: US drugmakers Merck and Moderna said Wednesday a personalised cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a “breakthrough.”
We haven't written up this one. New Straits Times has the full story — the link below goes straight to it.